CP
BTAI icon

Castleview Partners’s BioXcel Therapeutics BTAI Stock Holding History

Castleview Partners’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,080
Closed -$274K – 932
2024
Q1 		$274K Buy
+6,080
New +$290K 0.15% 145

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Castleview Partners's BTAI Position: Q2 2024 in Review

Castleview Partners sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 6,080 shares — an estimated $274K sold.

Castleview Partners first reported a position in BTAI in Q1 2024 and held it in 1 quarter. The position peaked at $274K in Q1 2024. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • Castleview Partners reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Castleview Partners sold 6,080 BioXcel Therapeutics shares in Q2 2024, an estimated $274K.
  • Castleview Partners first reported a position in BioXcel Therapeutics in Q1 2024 and held it in 1 quarter.
  • Castleview Partners's BioXcel Therapeutics position peaked at $274K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Castleview Partners's 13F filing for Q2 2024, filed 31 Jul 2024.